ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "systemic lupus erythematosus (SLE) and systemic sclerosis"

  • Abstract Number: 1961 • 2018 ACR/ARHP Annual Meeting

    Association of GTF2I Region Polymorphism with Systemic Lupus Erythematosus and Systemic Sclerosis, but Not with ANCA-Associated Vasculitis and Polymyositis/Dermatomyositis, in a Japanese Population

    Nozomi Yokoyama1,2, Aya Kawasaki1,2, Takashi Matsushita3, Hiroshi Furukawa1,2,4, Yuya Kondo5, Fumio Hirano6,7, Ken-ei Sada8, Isao Matsumoto5, Makio Kusaoi9, Hirofumi Amano9, Shohei Nagaoka10, Keigo Setoguchi11, Tatsuo Nagai12, Kota Shimada4,13, Shouji Sugii14, Atsushi Hashimoto15, Toshihiro Matsui16, Akira Okamoto17, Noriyuki Chiba18, Eiichi Suematsu19, Shigeru Ohno20, Masao Katayama21, Kiyoshi Migita22, Hajime Kono23, Minoru Hasegawa24, Shigeto Kobayashi25, Hidehiro Yamada26, Kenji Nagasaka27, Takahiko Sugihara28, Kunihiro Yamagata29, Shoichi Ozaki26, Manabu Fujimoto30, Naoto Tamura9, Yoshinari Takasaki9, Hiroshi Hashimoto31, Hirofumi Makino32, Yoshihiro Arimura33, Masayoshi Harigai34, Shinichi Sato35, Takayuki Sumida5, Shigeto Tohma36,37, Kazuhiko Takehara3 and Naoyuki Tsuchiya1,2, 1University of Tsukuba, Graduate School of Comprehensive Human Sciences, Masters' Program in Medical Sciences, Tsukuba, Japan, 2University of Tsukuba, Faculty of Medicine, Molecular and Genetic Epidemiology Laboratory, Tsukuba, Japan, 3Kanazawa University, Department of Dermatology, Kanazawa, Japan, 4National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Sagamihara, Japan, 5Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 6Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Department of Rheumatology, Tokyo, Japan, 7Tokyo Medical and Dental UniversityGraduate School of Medical and Dental Sciences, Department of Lifetime Clinical Immunology, Tokyo, Japan, 8Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama, Japan, 9Juntendo University, School of Medicine, Department of Internal Medicine and Rheumatology, Tokyo, Japan, 10Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, 11Allergy and Immunological Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, 12Kitasato University, Department of Rheumatology and Infectious Diseases, Sagamihara, Japan, 13Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, 14Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 15Rheumatology, National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, 16National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Kanagawa, Japan, 17Department of Rheumatology, Himeji Medical Center, National Hospital Organization, Himeji, Japan, 18Department of Rheumatology, Morioka Hospital, National Hospital Organization, Morioka, Japan, 19Clinical Research Institute, Department of Internal Medicine and Rheumatology, Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan, 20Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan, 21Department of Internal Medicine, Nagoya Medical Center, National Hospital Organization, Nagoya, Japan, 22Fukushima Medical University, School of Medicine, Fukushima, Japan, 23Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 24University of Fukui, Department of Dermatology, Fukui, Japan, 25Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, 26St. Marianna University, School of Medicine, Department of Internal Medicine, Kawasaki, Japan, 27Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, 28Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, 29University of Tsukuba, Faculty of Medicine, Department of Nephrology, Tsukuba, Japan, 30University of Tsukuba, Faculty of Medicine, Department of Dermatology, Tsukuba, Japan, 31Juntendo University School of Medicine, Tokyo, Japan, 32Okayama University Hospital, Okayama, Japan, 33Kyorin University School of Medicine, First Department of Internal Medicine, Tokyo, Japan, 34Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan, 35The University of Tokyo, Department of Dermatology, Tokyo, Japan, 36National Hospital Organization Tokyo National Hospital, Kiyose, Japan, 37National Hospital Organization Tokyo Hospital, Sagamihara, Japan

    Background/Purpose: Genome-wide association studies of systemic lupus erythematosus (SLE) in Chinese and Korean populations identified striking association with a single nucleotide polymorphism (SNP) rs73366469, located…
  • Abstract Number: 1966 • 2018 ACR/ARHP Annual Meeting

    Transcriptome and Methylome Integrative Molecular Analysis Uncovers a New Systemic Autoimmune Disease Classification

    Guillermo Barturen1, Sepideh Babaei2, Francesc Catala-Moll3, Zuzanna Makowska2, Antonio García-Gómez3, Anne Buttgereit4, Elena Carnero-Montoro1, Sikander Hayat4, Martin Kerick5, Thomas Charlon6, David C Gemperline7, Lucas Le Lann8, Rosa Quirantes-PIné9, Isabel Borrás-Linares10, Brian Muchmore1, Jorge Kageyama4, Javier Rodríguez-Ubreva3, Alvaro Fernández-Ochoa9, Pedro Carmona Sanz11, Christophe Jamin8, Ralf Lesche2, Robert J. Benschop7, Chris Chamberlain12, Ernst R. Dow7, Tania Gomes1, Maria Juárez13, Laurence Laigle14, Jacqueline Marovac12, Fiona MacDonald15, Jerome Wojcik6, Esteban Ballestar16, Lorenzo Beretta17, Maria Orietta Borghi18, Johan Frostegård19, Maria Luisa Garcia20, Javier Martín5, Jacques-Olivier Pers8, Yves Renadineau21, Antonio Segura Carretero9 and Marta Alarcón-Riquelme1,19, 1Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain, 2Pharmaceuticals Division, Bayer Pharma Aktiengesellschaft, Berlin, Germany, 3Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, 4Bayer Pharma Aktiengesellschaft, Berlin, Germany, 5Institute of Parasitology and Biomedicine López Neyra, Spanish National Research Council, Granada, Spain, 6QuartzBIO, SA, Geneva, Switzerland, 7Eli Lilly and Company, Indianapolis, IN, 8U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, 9Department of Analytical Chemistry, University of Granada, Granada, Spain, 10Analytical Chemistry, University of Granada, Granada, Spain, 11Unit of Bioinformatics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain, 12UCB Pharma, Slough, United Kingdom, 13UCB, Slough, United Kingdom, 14Institut de Recherches Internationales Servier, Suresnes, France, 15Bayer Pharma G, Berlin, Germany, 16Cancer Epigenetics and Biology Programme (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, 17Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, 18University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, 19Unit for Chronic Inflammatory Diseases, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 20Nano-Imaging, BIONAND. Centro Andaluz de Nanotecnología y Biomedicina, Malaga, Spain, 21U1227, Université de Brest, inserm, Labex IGO, CHU de brest, Brest, France

    Background/Purpose: Systemic autoimmune diseases (SADs) are chronic inflammatory conditions with autoimmune aetiology and many common clinical features, difficulting diagnosis and adequate treatment decisions. Finding new…
  • Abstract Number: 2377 • 2018 ACR/ARHP Annual Meeting

    Body Image in Rheumatic Diseases: A Systematic Review

    Shadi Gholizadeh1, Annie Meier2, Sarah D. Mills3 and Vanessa L. Malcarne4, 1Clinical Psychology, SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, 2Psychology, San Diego State University, San Diego, CA, 3Medicine, Lineberger Comprehensive Cancer Center University of North Carolina, Durham, NC, 4SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA

    Background/Purpose: In health conditions that cause changes in appearance, especially in areas of the body that are highly visible and socially salient (e.g., face and…
  • Abstract Number: 1639 • 2017 ACR/ARHP Annual Meeting

    Longitudinal Evolution in a Nationwide Cohort Originally Classified As Mixed Connective Tissue Disease

    Silje Reiseter1, Ragnar Gunnarsson2, Jukka Corander3, Johanna Haydon4, May Brit Lund5 and Øyvind Molberg1, 1Oslo University Hospital, Oslo, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, OSLO, Norway, 3Departement of Biostatistics, University of Oslo, Oslo, Norway, 4Rheumatology, Vestre Viken Hospital, Drammen, Norway, 5Respiratory Medicine, Oslo University Hospital, Oslo, Norway

    Background/Purpose: Ever since Mixed Connective Tissue Disease was presented as a distinct entity in 1972, it has been discussed whether MCTD represents an undifferentiated, transient…
  • Abstract Number: 2008 • 2017 ACR/ARHP Annual Meeting

    “Intrathoracic Manifestations of Connective Tissue Diseases on High Resolution Computed Tomography”

    Diego Baenas1, Maira Orozco2, María Eugenia Olmos3, Luis Lasca4, Paula Riba5, Patricio Muszinsky5, Juan Pablo Pirola6, Verónica Saurit7, Alejandro Alvarellos7, Ana C. Alvarez8, Soledad Retamozo9,10, Nadia Riscanevo7,11, Janet Flores12, Ariel Blua3, Ana María López13, Gustavo Muiño14, Santiago Orozco15 and Francisco Caeiro16, 1Rheumatology Unit, Hospital Privado Universitario de Córdoba, Postgraduate Career of Rheumatology Catholic University of Córdoba., Cordoba, Argentina, 2Radiology, Radiology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 3Pulmonary, Pulmonary Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 4Radiology Unit, Oulton Institute, Cordoba, Argentina, 5Radiology, Radiology Unit, Oulton Institute, Cordoba, Argentina, 6Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, 7Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 8Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Córdoba, Argentina, 9Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, 10Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, 11Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 12Rheumatology Unit, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 13Pulmonary Unit, Pulmonary Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, 14Radiology, Radiology Unit,Hospital Privado Universitario de Córdoba., Cordoba, Argentina, 15Radiology, Radiology Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, 16Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina

    Background/Purpose: Connective tissue diseases (CTD) can cause intrathoracic involvement, increasing patients morbidity and mortality. High-resolution computed tomography (HRCT) is a key method for evaluation of…
  • Abstract Number: 2681 • 2017 ACR/ARHP Annual Meeting

    Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome

    Samar Alharbi1, Zareen Ahmad2, Zahi Touma3, Arthur Bookman4, Jorge Sánchez-Guerrero5 and Sindhu Johnson6, 1Division of Rheumatology, University of Toronto, Toronto Scleroderma Program, Sinai Health System, University Health Network,, Toronto, ON, Canada, 2Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, 4Division of Rheumatology, University Health Network, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 5Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, 6Division of Rheumatology, University of Toronto, Toronto Scleroderma Program, Sinai Health Systems and University Health Network, Toronto, ON, Canada

    Background/Purpose: Systemic sclerosis (SSc) is an immune disorder characterized by vasculopathy and fibrosis. SSc may overlap with another disease such as systemic lupus erythematosus (SLE).…
  • Abstract Number: 1880 • 2015 ACR/ARHP Annual Meeting

    Circulating Microparticle Populations May Differentiate Between Connective Tissue Diseases. 

    Eoghan M. McCarthy1,2, Daniel Moreno-Martinez3, Fiona Wilkinson4, Neil J McHugh5,6, Ian N. Bruce7,8, Yvonne Alexander3, John D. Pauling6,9 and Ben Parker7,8, 1The University of Manchester, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, Mmanchester, United Kingdom, 2NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom, 3Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, 4School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom, 5Rheumatology, Bath Institute of Rheumatic Diseases, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 6Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, 7Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, 8Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 9Upper Borough Walls, Royal National Hospital for Rheumatic Disease, Bath, United Kingdom

     Background/Purpose: Microparticles (MPs) are membrane-bound vesicles derived from vascular and intravascular cells such as endothelial cells (EMPs) and platelets (PMPs). Circulating MPs levels are altered…
  • Abstract Number: 2964 • 2015 ACR/ARHP Annual Meeting

    Influences of Various Factors on Survival of Patients Treated with Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Patients with Connective Tissue Diseases

    Sumiaki Tanaka1, Yu Matsueda2, Eisuke Ogawa1, Jun Okada3 and Shunsei Hirohata1, 1Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, 2Rheumatology and Infectious diseases, Kitasato University School of Medicine, Kanagawa, Japan, 3Rheumatology, Kitasato University Hospital, Sagamihara, Japan

    Background/Purpose: In patients with connective tissue disease (CTD), especially systemic sclerosis (SSc), several mechanisms have been implicated for the development of pulmonary hypertension (PH), including…
  • Abstract Number: 2588 • 2013 ACR/ARHP Annual Meeting

    Pulmonary Hypertension In Patients With Anti-U1-RNP Antibodies

    Vincent Sobanski1, Bernadette Lynch2, Benjamin E. Schreiber3, Svetlana I. Nihtyanova4, Jennifer Harvey5, Clive Handler6, Christopher P. Denton7 and John G. Coghlan8, 1Department of Rheumatology, Royal Free Hospital, London, United Kingdom, 2Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, 3Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, 4Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 5Clinical Immunology, Royal Free Hospital, London, United Kingdom, 6Department of Pulmonary Hypertension, The Royal Free Hospital, London, United Kingdom, 7Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 8National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom

    Background/Purpose: Pulmonary hypertension (PH) is a leading cause of morbidity and mortality in patients with connective tissue diseases (CTD). Patients with anti-U1-RNP antibodies belong to…
  • Abstract Number: 619 • 2013 ACR/ARHP Annual Meeting

    Survival and Prognostic Factors In Patients With Connective Tissue Disease Associated Pulmonary Arterial Hypertension: Results From Korean Nationwide Registry

    Kwi Young Kang1, Chan Hong Jeon2, Sung Jae Choi3, Seung-Ki Kwok4, Seong-Kyu Kim5, Hyoun-Ah Kim6, Eon Jeong Nam7, Yong-Beom Park8, Kichul Shin9, Jaejoon Lee10, Chang-Hoon Lee11, Chan-Bum Choi12, Shin-Seok Lee13 and Dae-Hyun Yoo14, 1Rheumatology, Internal Medicine, Catholic University of Korea, Incheon St. Mary's Hospital, Seoul, South Korea, 2Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, 3Rheumatology, Korea University Medical Center, Seoul, South Korea, 4Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, 5Catholic University of Daegu School of Medicine, Daegu, South Korea, 6Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, 7Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, 8Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, 9Rheumatology, College of Medicine, Seoul National University, Seoul, South Korea, 10Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 11Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, 12Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, 14Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a major cause of mortality in connective tissue disease (CTD). We sought to quantify survival and determine factors predictive…
  • Abstract Number: 680 • 2012 ACR/ARHP Annual Meeting

    Plasma Level of Galectin-3 Binding Protein Reflects Type I Interferon Activity and Is Highly Increased in Patients with Systemic Lupus Erythematosus

    Christoffer T. Nielsen1, Ole Østergaard2, Line V. Iversen3, Christian Lood4, Anders A. Bengtsson4, Anne Voss5, Søren Jacobsen6 and Niels H. H. Heegaard3, 1Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen S, Denmark, 2Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institute, Copenhagen S, Denmark, 3Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, 4Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, 5Dept of Rheumatology, Odense University Hospital, Odense C, Denmark, 6Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

    Background/Purpose: Ongoing production of type I interferons (IFN) is a key element in the pathogenesis of systemic lupus erythematosus (SLE). Type I IFNs trigger the…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology